Groupon Falls; Cisc...
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$4.32 -0.04 | -0.92%
02/08/12 - 04:00 PM ET
431.48K / 662.40K
Vol / Avg. Vol:4.36 / 4.36
Open / Prev. Close:4.25 - 4.39
Today's Range:1.85 - 11.88
52 Wk Range:41.64%
Performance YTD:TheStreet Rating:
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
- UserTA stocks
- ContributorBarron's Activist Stocks 8-...
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- Contributor10 Biotech Stocks on Clinic...
- ContributorBarron's Insider Purchases ...
- User52 Week High Strategy
- UserJDShots PoBoy Portfolio
Latest DCTH Headlines from TheStreet
- Biotech Stock Mailbag: Mela Sciences 09.09.11 | 06:09 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- Biotech Stock Mailbag: Celsion 05.13.11 | 08:05 am
- 'Mad Money Lightning Round': Go for Exelixis 04.26.11 | 07:04 pm
- Biotech Stock Mailbag: Amarin 04.22.11 | 07:04 am
- Sweet Spot in Biotech Investing 04.13.11 | 12:04 pm
- Delcath: Safety Questions Behind FDA Delay 02.23.11 | 07:02 am
- Delcath Hit With FDA Approval Delay 02.22.11 | 10:02 am
- 10 Health Care Stocks With 100% Buy Ratings 01.28.11 | 07:01 am
- Biotech Stock Mailbag: Clinical Data, Mannkind and Thanks! 12.17.10 | 07:12 am
Press Releases for DCTH
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
- Delcath Submits CE Mark Technical File For Hepatic ChemoSAT⢠Delivery System - PR Newswire 12.06.10 | 06:12 am
- Delcath Names Bernard R. Tyrrell As Senior Vice President For North American Sales And Marketing - PR Newswire 12.01.10 | 06:12 am
- Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010 - Business Wire 11.10.10 | 05:11 pm
- Delcath Systems Announces Third Quarter Progress Report Conference Call - PR Newswire 10.27.10 | 06:10 am
- Delcath Strengthens Research And Development Team With Key Appointments - PR Newswire 10.20.10 | 04:10 pm
Partner Headlines for DCTH
- Company News for January 03, 2012 - Corporate Summary - Zacks 01.03.12 | 10:01 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Delcath Announces Updated Efficacy Results from Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver - Benzinga 09.23.11 | 06:09 pm
- Friday's Top Performing Small Cap Stocks (MDS, MNKD, FXCM, FOE, DCTH) - NASDAQ 08.15.11 | 01:08 pm
- A Pair of Medical Device Options Bets - Seeking Alpha 04.27.11 | 08:04 am
- Cramer's Mad Money - Buy the Villains of the Credit Crisis (4/14/11) - Seeking Alpha 04.15.11 | 07:04 am
- Biotech Catalysts for Q2 2011 - Seeking Alpha 04.07.11 | 09:04 am
- Delcath System's Two Chances of Legitimacy in 2011 - Seeking Alpha 02.17.11 | 08:02 am
- Delcath Systems Begins to Run Ahead of FDA NDA Response - Seeking Alpha 02.03.11 | 08:02 am
- Unconfirmed Rumors Circulate that Delcath Systems Inc. (DCTH) will receive FDA approval on product very soon major positive for stock - Benzinga 01.26.11 | 01:01 pm
